Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q4 2015 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, 2015
Slide 1: Agilent Technologies Q4'15 Results Presentation
Agilent Technologies Q4’15 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earning
Slide 3: Agilent Results Q4'15
Agilent Results Q4’15 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q4’15 Financial Metrics FY15 Highlights • Revenues: $1.035B, +6.2% y/y core(1)(2), -1% reported • Core Revenue Growth: 6.4%(1)(2) (-6.1% FX, -0.5% (-6.4% FX, -0.6% NMR, 0% M&A). Core growth dr
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Mixed core revenue growth across regions with Instrumentation and Informatics strength in the Americas and Pharma. for Analytical Laboratories • Operating Margin for the quarter was 20.0%(1)(2), down 20 bps versus last year. • Acquired Seahorse Bioscien
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Core revenue growth was strong across all Analytical Laboratory regions. Broad-based portfolio strength led by Consumables and Services Sample Prep, LC Columns, and Services. • Operating Margin in the quarter was 25.1%(1)(2), up 150 bps over last year. • New Offerings
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Continued momentum across all DGG Pathology, Genomics, and Businesses: Dako, Genomics, and Nucleic Acid Nucleic Acid Manufacturing Solutions. Target enrichment was particularly strong, while Omnis again had record shipments and continues to gain competitive win
Slide 7: Growth in a $45B Market – Q4'15 Results by End Market
Growth in a $45B Market – Q4’15 Results by End Market Strength in Pharma, Diagnostics & Clinical, and Food partly offset by weakness in Academia & Government and flat Environmental & Forensics, Chemical & Energy Analytical Laboratory End Markets Agilent Revenue by End Market (1) Q4’15 revenues: +6
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions On-Track to Deliver “Agile Agilent” Program Benefits • Multi-year program to increase efficiency and customer focus • New business group structure & portfolio • Consolidated Sales Channel • Central Research Lab Portfolio Investments • Completed acqui
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Accelerate Organic Growth • Focus on sustaining share growth within the core Analytical Lab • Continue to bring innovative new offerings to the market • Expand lab-wide services & consumables with a differentiated customer experience • Leverage An
Slide 10: Q1'16 and FY16 Guidance and Forward-looking Considerations
Q1’16 and FY16 Guidance and Forward-looking Considerations Based on October 30, 2015 Exchange Rates FY16 FY16 Guidance FY15 Guidance at • Revenue: $4.15B - $4.17B: growth at mid-point 4.25% core(4), 3% Actual (2) (1)(2) mid-point reported (1) (-1.2% NMR, +1.7% M&A, -1.7% FX) • Operating Margin: 19.7